Skip to main content
Top
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

Abnormal expression of CDK11p58 in prostate cancer

Authors: Yayun Chi, Lisha Wang, Xiuying Xiao, Ping Wei, Yiqin Wang, Xiaoyan Zhou

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

CDK11p58 is one of the large families of p34cdc2-related kinases whose functions are linked with cell cycle progression, tumorigenesis and apoptotic signaling. Our previous investigation demonstrated that CDK11p58 repressed androgen receptor (AR) transcriptional activity and was involved in the negative regulation of AR function.

Methods

CDK11p58 expression was examined in the prostate cancer tissues and adjacent tissues by IHC and qRT-PCR. Cell apoptosis was detected by flow cytometry. The metastasis of cancer cells was evaluated by the Transwell Assay. Finally we further investigated the underlying molecular mechanisms by examining expression levels of relevant proteins using western blot analysis.

Results

We found that both RNA and protein expression of CDK11p58 were low in prostate cancer tissues compared with its adjacent noncancerous tissues. CDK11p58 promoted the prostate cancer cell apoptosis and inhibited its metastasis in a kinase dependent way. And finally CDK11p58 could inhibit the metastasis of AR positive prostate cancer cells through inhibition of integrin β3 and MMP2.

Conclusions

These data indicate that CDK11p58 is an anti-metastasis gene product in prostate cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chen C, Yan J, Sun Q, Yao L, Jian Y, Lu J, Gu J: Induction of apoptosis by p110C requires mitochondrial translocation of the proapoptotic BCL-2 family member BAD. Febs Lett. 2006, 580 (3): 813-821. 10.1016/j.febslet.2005.12.097.CrossRefPubMed Chen C, Yan J, Sun Q, Yao L, Jian Y, Lu J, Gu J: Induction of apoptosis by p110C requires mitochondrial translocation of the proapoptotic BCL-2 family member BAD. Febs Lett. 2006, 580 (3): 813-821. 10.1016/j.febslet.2005.12.097.CrossRefPubMed
2.
go back to reference Harper JW, Adams PD: Cyclin-dependent kinases. Chem Rev. 2001, 101 (8): 2511-2526. 10.1021/cr0001030.CrossRefPubMed Harper JW, Adams PD: Cyclin-dependent kinases. Chem Rev. 2001, 101 (8): 2511-2526. 10.1021/cr0001030.CrossRefPubMed
3.
go back to reference Trembley JH, Loyer P, Hu D, Li T, Grenet J, Lahti JM, Kidd VJ: Cyclin dependent kinase 11 in RNA transcription and splicing. Prog Nucleic Acid Res Mol Biol. 2004, 77: 263-288.CrossRefPubMed Trembley JH, Loyer P, Hu D, Li T, Grenet J, Lahti JM, Kidd VJ: Cyclin dependent kinase 11 in RNA transcription and splicing. Prog Nucleic Acid Res Mol Biol. 2004, 77: 263-288.CrossRefPubMed
4.
go back to reference Zong H, Chi Y, Wang Y, Yang Y, Zhang L, Chen H, Jiang J, Li Z, Hong Y, Wang H: Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor. Mol Cell Biol. 2007, 27 (20): 7125-7142. 10.1128/MCB.01753-06.CrossRefPubMedCentralPubMed Zong H, Chi Y, Wang Y, Yang Y, Zhang L, Chen H, Jiang J, Li Z, Hong Y, Wang H: Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor. Mol Cell Biol. 2007, 27 (20): 7125-7142. 10.1128/MCB.01753-06.CrossRefPubMedCentralPubMed
5.
go back to reference Wang L, Hsu CL, Chang C: Androgen receptor corepressors: an overview. Prostate. 2005, 63 (2): 117-130. 10.1002/pros.20170.CrossRefPubMed Wang L, Hsu CL, Chang C: Androgen receptor corepressors: an overview. Prostate. 2005, 63 (2): 117-130. 10.1002/pros.20170.CrossRefPubMed
6.
go back to reference Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C, Mizokami A: Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr. 1995, 5 (2): 97-125. 10.1615/CritRevEukarGeneExpr.v5.i2.10.CrossRefPubMed Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C, Mizokami A: Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr. 1995, 5 (2): 97-125. 10.1615/CritRevEukarGeneExpr.v5.i2.10.CrossRefPubMed
7.
go back to reference Heinlein CA, Chang C: Androgen receptor (AR) coregulators: an overview. Endocr Rev. 2002, 23 (2): 175-200.CrossRefPubMed Heinlein CA, Chang C: Androgen receptor (AR) coregulators: an overview. Endocr Rev. 2002, 23 (2): 175-200.CrossRefPubMed
8.
go back to reference Levesque MH, El-Alfy M, Cusan L, Labrie F: Androgen receptor as a potential sign of prostate cancer metastasis. Prostate. 2009, 69 (15): 1704-1711. 10.1002/pros.21021.CrossRefPubMed Levesque MH, El-Alfy M, Cusan L, Labrie F: Androgen receptor as a potential sign of prostate cancer metastasis. Prostate. 2009, 69 (15): 1704-1711. 10.1002/pros.21021.CrossRefPubMed
9.
go back to reference Wang X, Lee SO, Xia S, Jiang Q, Luo J, Li L, Yeh S, Chang C: Endothelial cells enhance prostate cancer metastasis via IL-6- > Androgen Receptor- > TGF-beta- > MMP-9 signals. Mol Cancer Ther. 2013, 12 (6): 1026-1037. 10.1158/1535-7163.MCT-12-0895.CrossRefPubMedCentralPubMed Wang X, Lee SO, Xia S, Jiang Q, Luo J, Li L, Yeh S, Chang C: Endothelial cells enhance prostate cancer metastasis via IL-6- > Androgen Receptor- > TGF-beta- > MMP-9 signals. Mol Cancer Ther. 2013, 12 (6): 1026-1037. 10.1158/1535-7163.MCT-12-0895.CrossRefPubMedCentralPubMed
10.
go back to reference Liu YN, Liu Y, Lee HJ, Hsu YH, Chen JH: Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol. 2008, 28 (23): 7096-7108. 10.1128/MCB.00449-08.CrossRefPubMedCentralPubMed Liu YN, Liu Y, Lee HJ, Hsu YH, Chen JH: Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol. 2008, 28 (23): 7096-7108. 10.1128/MCB.00449-08.CrossRefPubMedCentralPubMed
11.
go back to reference Ma WL, Hsu CL, Yeh CC, Wu MH, Huang CK, Jeng LB, Hung YC, Lin TY, Yeh S, Chang C: Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology. 2012, 56 (1): 176-185. 10.1002/hep.25644.CrossRefPubMedCentralPubMed Ma WL, Hsu CL, Yeh CC, Wu MH, Huang CK, Jeng LB, Hung YC, Lin TY, Yeh S, Chang C: Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology. 2012, 56 (1): 176-185. 10.1002/hep.25644.CrossRefPubMedCentralPubMed
12.
go back to reference Jung SJ, Oh S, Lee GT, Chung J, Min K, Yoon J, Kim W, Ryu DS, Kim IY, Kang DI:Clinical significance of Wnt/beta-catenin signalling and androgen receptor expression in prostate cancer. World J Mens Health. 2013, 31 (1): 36-46. 10.5534/wjmh.2013.31.1.36.CrossRefPubMedCentralPubMed Jung SJ, Oh S, Lee GT, Chung J, Min K, Yoon J, Kim W, Ryu DS, Kim IY, Kang DI:Clinical significance of Wnt/beta-catenin signalling and androgen receptor expression in prostate cancer. World J Mens Health. 2013, 31 (1): 36-46. 10.5534/wjmh.2013.31.1.36.CrossRefPubMedCentralPubMed
Metadata
Title
Abnormal expression of CDK11p58 in prostate cancer
Authors
Yayun Chi
Lisha Wang
Xiuying Xiao
Ping Wei
Yiqin Wang
Xiaoyan Zhou
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-14-2

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine